Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

213
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
213
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

10.6K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.6K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

485
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
485
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

141
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
141

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Mobile Health Platform for Heart Failure Self-Management: Feasibility Study on Patient Engagement, Acceptance, and Potential Health Outcomes.

JMIR formative research·2026
Same author

Artificial intelligence in healthcare: a qualitative study exploring consumer perspectives.

BMC medical ethics·2026
Same author

Co-design of Lifestyle6, a digital tool targeting multiple health behaviour changes for cancer risk reduction and early detection support.

PloS one·2026
Same author

Most digital psychological interventions for chronic pain fail to measure all 4 dimensions of the quadruple aim of value-based health care: a scoping review.

Pain·2026
Same author

Digitising Medical Nutrition Therapy in Gestational Diabetes: A Multisite Pilot Study.

Nursing research and practice·2026
Same author

Using Citizen Science to Address Out-of-Pocket Healthcare Expenditure with Aboriginal Communities in the Far West of South Australia: A Protocol.

International journal of environmental research and public health·2025

Related Experiment Video

Updated: May 13, 2025

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

138

Digital Health Interventions to Prevent Type 2 Diabetes Mellitus: Systematic Review.

Tuan Duong1,2, Quita Olsen1, Anish Menon1,3

  • 1Queensland Digital Health Centre, Faculty of Medicine, The University of Queensland, Brisbane, Australia.

Journal of Medical Internet Research
|April 25, 2025
PubMed
Summary

Digital health interventions (DHIs) show benefits for population health in type 2 diabetes mellitus (T2DM) management. Combining DHIs with health care provider interaction is key for preventing T2DM and improving blood glucose control.

Keywords:
PRISMAdigital healthdigital health interventionprediabetespreventtype 2 diabetes

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.7K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.7K

Related Experiment Videos

Last Updated: May 13, 2025

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

138
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.7K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.7K

Area of Science:

  • Digital health interventions
  • Type 2 Diabetes Mellitus (T2DM) management
  • Healthcare system optimization

Background:

  • Digital health interventions (DHIs) are transforming healthcare.
  • The quadruple aims (population health, consumer experience, provider experience, cost reduction) guide DHI development.
  • Impact of DHIs on T2DM burden across the quadruple aims remains unclear.

Purpose of the Study:

  • Systematically review DHI effects on T2DM burden.
  • Assess impact through the lens of the quadruple aims.
  • Identify effective DHI strategies for T2DM prevention and management.

Main Methods:

  • Searched PubMed, Embase, CINAHL, Web of Science (Jan 2014-Mar 2024).
  • Assessed primary outcomes: T2DM development, HbA1c, blood glucose; secondary: consumer/provider experience, costs.
  • Categorized DHIs and evaluated effects using Cochrane RoB 2 and ROBINS-I tools.

Main Results:

  • 53 papers included; limited evidence on T2DM development (1 positive study).
  • Positive effects on dysglycemia (blood glucose) in 43.4% of studies; mixed consumer experience.
  • Lack of data on provider experience and healthcare costs; combined DHIs and HCP interaction showed positive outcomes.

Conclusions:

  • DHIs show benefits for population health in T2DM but require comprehensive assessment across all quadruple aims.
  • Mixed results for consumer experience; insufficient data on provider experience and costs.
  • Combined DHIs with HCP interaction are crucial for effective T2DM prevention and dysglycemia management.